PATENT CLAIM ANALYSIS

Application Number: 15744278
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["424", "134100"]

Abstract:
Disclosed is a fusion polypeptide for inhibiting neovascularization, including a peptide specifically binding to vascular endothelial growth factor (VEGF) receptors, and a hydrophilic elastin-based polypeptide (hydrophilic EBP) linked to the peptide.

Claim (Index 10):
The fusion polypeptide according to  claim 1 , wherein the fusion polypeptide is consisted of an amino acid sequence corresponding to SEQ ID NO. 48, SEQ ID NO. 49, SEQ ID NO. 50 or SEQ ID NO. 51.

Metadata:
- Claim Count in Document: 10.0
- Percentile: 86.0
- Lexical Diversity: 1.31034
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14917460', '14740194', '12789215', '14740158', '14442376']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7372251758068195
- 35 USC 102 Novelty (BERT): 0.5197081638681738
- Combined Prediction Score: 0.7154734746129549
- Mean Citation Score: 259.111848
- Max Citation Score: 305.7306
- Similarity Product: 231.88998437232968

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test